Revenue for CVRx climbs to 13.8 million dollars with U.S. implanting centers reaching 262

Revenue for CVRx climbs to 13.8 million dollars with U.S. implanting centers reaching 262
CVRx revenue hits 13.8 million dollars

CVRx announced its financial results for the third quarter, posting total revenue of 13.8 million dollars. U.S. revenue accounted for 13.0 million dollars during the period.

The number of active U.S. implanting centers rose to 262, up from 250 previously. The company also provided a business outlook for 2026, highlighting recent operational milestones.

CVRx recently supported Endeavor Health’s first Barostim procedure to expand heart failure treatment options. The company also reported the first BENEFIT-HF trial participant implanted in Ohio by The Christ Hospital team. These developments mark steps in advancing Barostim therapy and clinical research initiatives.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.